The Unified Parkinson's Disease Rating Scale (UPDRS) is the primary outcome measure in most clinical trials of Parkinson's disease (PD) therapeutics. Each subscore of the motor section (UPDRS III) compresses a wide range of motor performance into a coarse-grained scale from 0 to 4; the assessment of performance can also be subjective. Quantitative digitography (QDG) is an objective, quantitativ...

Telemonitoring of Parkinson's Disease (PD) has attracted considerable research interest because its potential to make a lasting, positive impact on the life patients and their carers. Purpose-built devices have been developed that record various signals which can be associated with average PD symptom severity, as quantified standard clinical metrics such Unified Rating Scale (UPDRS). Speech are...

This study examined the effect of improvements in timing/rhythmicity on students’ reading achievement. 86 participants completed preand post-test measures of reading achievement (i.e., Woodcock-Johnson III, Comprehensive Test of Phonological Processing, Test of Word Reading Efficiency, and Test of Silent Word Reading Fluency). Students in the experimental group completed a 4-week intervention d...

b a c k ground: several studies have indicated that executive dysfunction is the main neuropsychological feature of parkinson’s disease (pd). the frontal assessment battery (fab) is a short tool for the assessment of executive functions. p u r p o s e : the aim of this study was to determine the relationship between persian version of fab scores and age, education, mini-mental state examination...

The ability to arise from a sitting standing position is often impaired in Parkinson's disease (PD). This impairment associated with an increased risk of falling, and higher dementia. We propose novel approach estimate Movement Disorder Society Unified PD Rating Scale (MDS-UPDRS) ratings for “item 3.9” (arising chair) using computer vision-based method, whereby we use clinically informed reason...

Parkinson's Disease (PD) affects nearly a million Americans, number that will increase over the coming decades. L-DOPA has been most effective treatment. While available medical therapies help control symptoms during initial years following diagnosis, higher doses are required time, increasing side effects and decreasing of symptoms. As result, patients suffering from PD become refractory to co...

Clinical relevance of MAO-B inhibitors 2 ARC Publishing Introduction The monoamine oxidase-B inhibitors (MAO-B) have a prominent place in the treatment of Parkinson's disease (PD), especially in the early stages of the disease, both for their contribution to the delay of Levodopa (LD) treatment initiation, and for their much talked neuroprotective role [1-3]. However, questions have been raised...

Deep brain stimulation (DBS) is regarded as a feasible Parkinson’s disease (PD) treatment option. The subthalamic nucleus (STN) and globus pallidus (GPi) are the two most common sites for DBS. following criteria were used to select studies that examined Unified PD Rating Scale (UPDRS) III: (1) had at least three months of follow-up; (2) compared both GPi STN-DBS; (3) each group included five in...

Abstract Background To investigate the relationship between position of bilateral STN-DBS location active contacts and clinical efficacy on motor symptoms in Parkinson’s disease (PD) patients. Methods Retrospectively analyze data 57 patients with PD who underwent from March 2018 to December 2018. Unified Disease Rating Scale-Part III (UPDRS-III) score, levodopa equivalent day dose (LEDD), Quali...